Limited T-20 Compassionate Use Program Launches in OctoberSeptember/October 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Individuals with HIV who are in need of a salvage therapy and who meet certain criteria may be able to access T-20, also known as Fuzeon, through a compassionate use program expected to begin in October. T-20, a member of a new class of drugs called fusion inhibitors, is administered by injection twice a day. FDA approval of the drug is expected soon. Only 600 slots in the program are available. Individuals enrolling in the program must be 6 years old or older, have a viral load greater than 10,000 copies and a CD4 count of less than 100 cells/mm3 while on highly active antiretroviral therapy. Individuals must also "be limited by the currently commercial available antiretroviral agents as per the judgment of the investigator," according to a letter announcing the program.
Back to the September/October 2002 issue of Positive Living.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.
|
|